Insider trade

Director sold ~$113K of CSTL shares in the open market

Traded Sep 21, 2026 · Filed Sep 24, 2026

Why it stands out

A Castle Biosciences director sold $113K of Castle Biosciences shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

DirectorIndirect holding$100K–$500KPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$112,998

Shares × reported transaction price

Timing vs results

53 days after results of Jul 30, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

These transactions were made pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on June 2, 2026.
This transaction was executed in multiple trades at prices ranging from $35.020 to $35.665, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Held by The Maetzold Descendants 2020 Trust of which the Reporting Person's spouse is the trustee and the Reporting Person's spouse and their children are beneficiaries.

Filed yesterday

Traded Oct 1 · filed 5 days later

Derivative exercise or conversion — not an open-market buy.

Planned saleFiled yesterday

Planned saleFiled yesterday